Biotech Newcomer to Purchase Sanofi Plant in Allston

National Resilience, a biotech newcomer launched in November 2020 and headquartered in Boston and San Diego, is poised to purchase the Sanofi bio-manufacturing plant in Allston. According to its website, Resilience “will actively invest in developing powerful new technologies to manufacture complex medicines that are defining the future of therapeutics, including cell and gene therapies, viral vectors, vaccines, and proteins. In doing so, it seeks to overcome one of the biggest challenges the biopharmaceutical industry is facing in pioneering novel treatment modalities – manufacturing.”

“We created Resilience to reimagine biopharmaceutical manufacturing through unprecedented investment in technology and a best-in-class team to execute our vision,” said Robert Nelsen, Resilience founder, Chairman of the Board, and managing director at ARCH Venture Partners. “COVID-19 has exposed critical vulnerabilities in medical supply chains, and today’s manufacturing can’t keep up with scientific innovation, medical discovery, and the need to rapidly produce and distribute critically important drugs at scale. We are committed to tackling these huge problems with a whole new business model.”

Resilience has raised over $800 million of capital following the recent Series B raise of approximately $750 million, not tied to milestones, from investors that collectively manage over $5 trillion. Led by ARCH Venture Partners and 8VC with participation by GV and NEA, investors include public mutual funds, some of the largest U.S.-based pharmaceutical companies, foundations, family offices, and pension funds, among others. (Source: Resilience Website, 23 November, 2020)